Még nem toboroz
Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer With a High Tumor Burden
NCT07715396· 3. fázis· AIO-Studien-gGmbH· Forrás
Toboroz
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)
NCT07680790· 3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
A Phase IIb Study to Evaluate AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)
2025-525016-41-00· 2. fázis· AstraZeneca AB· Forrás
Még nem toboroz
A Trial for the Treatment of Advanced Large-Cell Neuroendocrine Cancer of the Lung
NCT07561645· 2. fázis· Technische Universität Dresden· Forrás
Toboroz
Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)
NCT07284602· 3. fázis· PureTech· Forrás
Toboroz
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566· 3. fázis· Pfizer· Forrás
Toboroz
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
NCT07063745· 2/3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
Osimertinib plus chemotherapy as 1st line therapy in stage IV NSCLC patients with atypical EGFR mutations (AIO-TRK/YMO-0324)
2024-516790-78-00· 2. fázis· Universitat Heidelberg· Forrás
Toboroz
Study of Sacituzumab Govitecan Versus Standard of Care in Participants with Previously Treated Extensive Stage Small Cell Lung Cancer
2024-515884-69-00· 3. fázis· Gilead Sciences Inc.· Forrás
Toboroz
Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis
NCT06315010· 2. fázis· MedSIR· Forrás
Toboroz
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
NCT06875310· 3. fázis· Mirati Therapeutics Inc.· Forrás
Toboroz
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
NCT06772623· 1/2. fázis· AbbVie· Forrás
Toboroz
Study to Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With Extensive Stage Small-cell Lung Cancer With Poor Performance Status
NCT07803848· 2. fázis· AIO-Studien-gGmbH· Forrás
Toboroz
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
NCT06627647· 3. fázis· AstraZeneca· Forrás
Toboroz
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738· 3. fázis· AstraZeneca· Forrás
Fut, nem toboroz
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
NCT06465329· 2. fázis· Regeneron Pharmaceuticals· Forrás
Meghívásos bevonás
Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)
NCT06419179· 2. fázis· University of Cologne· Forrás
Fut, nem toboroz
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
NCT06238622· 3. fázis· Boehringer Ingelheim· Forrás
Fut, nem toboroz
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
NCT06497556· 3. fázis· Hoffmann-La Roche· Forrás
Toboroz
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
NCT06452277· 3. fázis· Bayer· Forrás
Fut, nem toboroz
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery
NCT06161441· 2. fázis· Regeneron Pharmaceuticals· Forrás
Toboroz
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
NCT06312137· 3. fázis· Merck Sharp & Dohme LLC· Forrás
Fut, nem toboroz
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
NCT06012435· 3. fázis· Seagen, a wholly owned subsidiary of Pfizer· Forrás
Fut, nem toboroz
Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study
NCT05089916· 2. fázis· AIO-Studien-gGmbH· Forrás
Fut, nem toboroz
A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung
NCT05470595· 2. fázis· Technische Universität Dresden· Forrás
Fut, nem toboroz
Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN)
NCT04602533· 2. fázis· Michael Hopp· Forrás
Toboroz
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
NCT04613596· 2/3. fázis· Mirati Therapeutics Inc.· Forrás
Fut, nem toboroz
Prospective Phase-II Trial of induction chemotherapy and
chemoradiotherapy plus/minus the PD-L1 antibody durvalumab followed
by surgery or definitive chemoradiation boost and consolidation
durvalumab in resectable stage III NSCLC
NCT04202809· 2. fázis· Universitaetsklinikum Essen AöR· Forrás